We use cookies to ensure that the website works as intended and to collect statistics on its use so that we can improve your web site experience.

×

Aker BioMarine - first quarter 2022

29 April 2022: Aker BioMarine ASA (“Aker BioMarine” or “the company”) reports revenues of USD 56.9 million and Adjusted...

Aker BioMarine - results for the fourth quarter and full year 2021

Aker BioMarine ASA (“Aker BioMarine” or “the company”) reports revenues of USD 75.7 million and Adjusted EBITDA of USD 7.2...

Aker BioMarine appoints new EVP for Human Health & Nutrition business area

Simon Seward has been appointed EVP of Human Health & Nutrition in Aker BioMarine ASA from today. He is an industry leader...

New Study: Krill Oil Significantly Reduces Major Cardiovascular Risk Factors

A ‘game-changer’ within heart health, says researcher. Krill oil significantly reduces triglyceride levels in the blood - an...

Aker BioMarine appoints SVP Investor Relations

Aker BioMarine ASA is pleased to announce that Carl Christian Bachke has been appointed SVP Investor Relations effective...

Aker BioMarine appoints Douglas C. Hicks as SVP, Business Development & Strategy

Aker BioMarine, the global biotech innovator and world-leading supplier of krill, announces the appointment of biotechnology...

Aker BioMarine lists on Oslo Børs

Euronext today congratulates Aker BioMarine on its transfer from Euronext Growth to Oslo Børs (ticker code: AKBM).

Aker BioMarine commits to industry-leading emissions-free operations in Antarctica

Aker BioMarine launches its ambitious sustainability goals towards 2030.

Fourth quarter 2020: Promising new product launches and adjusted EBITDA growth of 2.5x YoY

Aker BioMarine today announces its results for the fourth quarter 2020.